Myositis Specific 11 Antibody Panel : 94777

MYOSIT or 94777

Jo-1; Mi-2; PL-7; PL-12; EJ; SRP; OJ; NXP2; MDA5; TIF1-gamma; CADM140; Autoimmune myopathy; NuRD Complex; JDM; Polymyositis; SRP Signal recognition protein AB; Necrotizing myopathy; Paraneoplastic myositis; TIF 1-gamma antibody; Dermatomyositis; Transf

This panel includes: Jo-1 Ab, PL-7 Ab, PL-12 Ab, EJ Ab, OJ Ab, SRP Ab, Mi-2 Alpha Ab, Mi-2 Alpha Ab, Mi-2 Beta Ab, MDA5 Ab, TIF1 Gamma Ab, NXP-2 Ab.

Serum separator tube.

Centrifuge serum separator tube and transport. 0.5 mL serum, (Min: 0.3 mL)

Refrigerated.

After separation from cells: Ambient: 7 days; Refrigerated: 14 days; Frozen: 28 days

Tuesday - Saturday

4-6 days (From receipt at performing laboratory)

These tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. They have not been cleared or approved by the FDA. These assays have been validated pursuant to the CLIA regulations and are used for clinical purposes.

Jo-1 Ab less than 11 SI
PL-7 Ab less than 11 SI
PL-12 Ab less than 11 SI
EJ Ab less than 11 SI
OJ Ab less than 11 SI
SRP Ab less than 11 SI
Mi-2 Alpha Ab less than 11 SI
Mi-2 Beta Ab less than 11 SI
MDA-5 Ab less than 11 SI
TIF-1y Ab less than 11 SI
NXP-2 Ab less than 11 SI

Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodelling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.